These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 22548975)
21. Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma. Lautscham EM; Kessler M; Ernst T; Willimzig L; Neiger R Vet Rec; 2017 Mar; 180(12):303. PubMed ID: 28100766 [TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. Saba CF; Thamm DH; Vail DM J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160 [TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas. Childress MO; Ramos-Vara JA; Ruple A J Am Vet Med Assoc; 2016 Nov; 249(9):1067-1078. PubMed ID: 27767437 [TBL] [Abstract][Full Text] [Related]
24. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
25. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158 [TBL] [Abstract][Full Text] [Related]
26. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma. Saba CF; Hafeman SD; Vail DM; Thamm DH J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892 [TBL] [Abstract][Full Text] [Related]
27. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). Fahey CE; Milner RJ; Barabas K; Lurie D; Kow K; Parfitt S; Lyles S; Clemente M J Am Vet Med Assoc; 2011 Jul; 239(2):209-15. PubMed ID: 21756176 [TBL] [Abstract][Full Text] [Related]
29. Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma. Gan H; Zhang F; Lin Y Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):397-9. PubMed ID: 12408775 [TBL] [Abstract][Full Text] [Related]
30. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma. Benjamin SE; Sorenmo KU; Krick EL; Salah P; Walsh KA; Weinstein NM; Keuler NS; Avery AC; Atherton MJ; Lenz JA Vet Comp Oncol; 2021 Sep; 19(3):541-550. PubMed ID: 33729654 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs. Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147 [TBL] [Abstract][Full Text] [Related]
32. Asparaginase and MOPP treatment of dogs with lymphoma. Brodsky EM; Maudlin GN; Lachowicz JL; Post GS J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842 [TBL] [Abstract][Full Text] [Related]
33. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma. Elliott JW; Cripps P; Marrington AM; Grant IA; Blackwood L Vet Comp Oncol; 2013 Sep; 11(3):185-98. PubMed ID: 22372620 [TBL] [Abstract][Full Text] [Related]
34. Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. Perry JA; Thamm DH; Eickhoff J; Avery AC; Dow SW Vet Comp Oncol; 2011 Mar; 9(1):55-64. PubMed ID: 21303454 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Moore AS; Cotter SM; Rand WM; Wood CA; Williams LE; London CA; Frimberger AE; L'Heureux DA J Vet Intern Med; 2001; 15(4):348-54. PubMed ID: 11467592 [TBL] [Abstract][Full Text] [Related]
36. Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. Lori JC; Stein TJ; Thamm DH Vet Comp Oncol; 2010 Sep; 8(3):188-95. PubMed ID: 20691026 [TBL] [Abstract][Full Text] [Related]
37. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574 [TBL] [Abstract][Full Text] [Related]
38. Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results. Zandvliet M; Rutteman GR; Teske E Vet J; 2013 Sep; 197(3):656-61. PubMed ID: 23746872 [TBL] [Abstract][Full Text] [Related]
39. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B; Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635 [TBL] [Abstract][Full Text] [Related]
40. Rectal lymphoma in 11 dogs: a retrospective study. Van den Steen N; Berlato D; Polton G; Dobson J; Stewart J; Maglennon G; Hayes AM; Murphy S J Small Anim Pract; 2012 Oct; 53(10):586-91. PubMed ID: 22882127 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]